TY - JOUR
T1 - Pharmacotherapy for recurrent ovarian cancer
T2 - Current status and future perspectives
AU - Matsumoto, Koji
AU - Onda, Takashi
AU - Yaegashi, Nobuo
N1 - Funding Information:
The study was supported in part by the National Cancer Center Research and Development Funds (23-A-16, 23-A-17 and 26-A-4), the Grant-in-Aid for Clinical Cancer Research (17S-1, 17S-5, 18-6, 20S-1 and 20S-6) from the Ministry of Health, Labor and Welfare of Japan.
Publisher Copyright:
© The Author 2015. Published by Oxford University Press. All rights reserved.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Several 'lines of therapy' that utilize cytotoxic agents and are driven by platinum-free intervals are the current standard of care for patients with recurrent ovarian cancer. For patients with platinum-resistant disease, single agent chemotherapy (pegylated liposomal doxorubicin, topotecan, gemcitabine or weekly paclitaxel) is the standard of care. For patients with platinum-sensitive disease, combination chemotherapy (carboplatin plus paclitaxel, pegylated liposomal doxorubicin or gemcitabine) is the standard of care. In addition, antiangiogenic therapy using bevacizumab is an established option. Future directions could include 'lines of therapy' with biologic agents driven by specific biologic targets. Data from antiangiogenic agents (trebananib, pazopanib and cediranib), antifolate drugs (farletuzumab and vintafolide), poly(ADP-ribose) polymerase inhibitors (olaparib and veliparib), mTOR inhibitors (everolimus and temsirolimus) and immune editing agents (nivolumab) have been summarized in this review.
AB - Several 'lines of therapy' that utilize cytotoxic agents and are driven by platinum-free intervals are the current standard of care for patients with recurrent ovarian cancer. For patients with platinum-resistant disease, single agent chemotherapy (pegylated liposomal doxorubicin, topotecan, gemcitabine or weekly paclitaxel) is the standard of care. For patients with platinum-sensitive disease, combination chemotherapy (carboplatin plus paclitaxel, pegylated liposomal doxorubicin or gemcitabine) is the standard of care. In addition, antiangiogenic therapy using bevacizumab is an established option. Future directions could include 'lines of therapy' with biologic agents driven by specific biologic targets. Data from antiangiogenic agents (trebananib, pazopanib and cediranib), antifolate drugs (farletuzumab and vintafolide), poly(ADP-ribose) polymerase inhibitors (olaparib and veliparib), mTOR inhibitors (everolimus and temsirolimus) and immune editing agents (nivolumab) have been summarized in this review.
KW - Chemo-gynecology
KW - Gynecol-med
KW - Molecular Dx
UR - http://www.scopus.com/inward/record.url?scp=84930002370&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930002370&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyv014
DO - 10.1093/jjco/hyv014
M3 - Review article
C2 - 25765457
AN - SCOPUS:84930002370
SN - 0368-2811
VL - 45
SP - 408
EP - 410
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
IS - 5
ER -
